Recent Updates
Recently added Catalysts
VNDA

Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference

Tuesday, October 10, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: WASHINGTON, Oct. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will host investor meetings at the Oppenheimer Specialty Pharma Summit Conference in New York City on Wednesday, October 11, 2017. About Vanda Pharmaceuticals Inc.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
19.9%
average across 7 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Imsidolimab
Phase 2 · Palmoplantar Pustulosis

Full Press Release Details

WASHINGTON, Oct. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will host investor meetings at the Oppenheimer Specialty Pharma Summit Conference in New York City on Wednesday, October 11, 2017.
About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda, please visit www.vandapharma.com.
Executive Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
ShareAdd on Google
Tags: VNDA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 10, 2017

Biotech snapshot

Cash runway
$170M liquidity · $10M/mo burn
~16 mo
Low dilution risk
Lead asset
ImsidolimabPhase 2
Palmoplantar Pustulosis →

Catalyst track record

+121%
best trade around VNDA's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for VNDA.

See every catalyst's timing & PoA →